Ultragenyx Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Ultragenyx Pharmaceutical has a total shareholder equity of $140.3M and total debt of $891.4M, which brings its debt-to-equity ratio to 635.5%. Its total assets and total liabilities are $1.3B and $1.2B respectively.
Key information
635.5%
Debt to equity ratio
US$891.41m
Debt
| Interest coverage ratio | n/a |
| Cash | US$412.08m |
| Equity | US$140.26m |
| Total liabilities | US$1.17b |
| Total assets | US$1.31b |
Recent financial health updates
We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24
Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Needs To Drive Business Growth Carefully
May 19Recent updates
Shareholders Will Probably Hold Off On Increasing Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) CEO Compensation For The Time Being
Jun 12Ultragenyx: Modest Sales Growth, With Multiple Inflection Points Approaching
Jun 06We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Has A Fair Chunk Of Debt
May 24Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet
Mar 09Will Ultragenyx Pharmaceutical (NASDAQ:RARE) Spend Its Cash Wisely?
Feb 01There's No Escaping Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Muted Revenues Despite A 28% Share Price Rise
Dec 28Is There An Opportunity With Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) 47% Undervaluation?
Sep 12An Intrinsic Calculation For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Suggests It's 50% Undervalued
May 24Improved Revenues Required Before Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Find Their Feet
Apr 17Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 33% Below Their Intrinsic Value Estimate
Feb 18Ultragenyx upgraded to buy at Guggenheim as stock trading at discount to biotech peers
Oct 13Ultragenyx grants stock options, restricted stock units
Oct 05Ultragenyx Pharmaceuticals: Downward Trajectory Likely To Continue
Sep 02Ultragenyx sells part of North American royalties on Crysvita to OMERS for $500M
Jul 14Ultragenyx: Convincing Investment Thesis For This Orphan Drug Developer
Jun 20We Think Ultragenyx Pharmaceutical (NASDAQ:RARE) Needs To Drive Business Growth Carefully
May 19Financial Position Analysis
Short Term Liabilities: RARE's short term assets ($596.0M) exceed its short term liabilities ($245.6M).
Long Term Liabilities: RARE's short term assets ($596.0M) do not cover its long term liabilities ($921.2M).
Debt to Equity History and Analysis
Debt Level: RARE's net debt to equity ratio (341.7%) is considered high.
Reducing Debt: RARE's debt to equity ratio has increased from 0% to 635.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RARE has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 12.9% each year.